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Abstract: Statins have emerged at the forefront of preventive cardiology and have significantly 
reduced cardiovascular events and mortality. Nonetheless, cardiovascular disease remains the 
leading cause of death in the United States and in other developed countries, as well as the 
etiology of significant morbidity and health-care expenditure. In an attempt to reduce potentially 
missed opportunities for instituting preventive therapy, the JUPITER study (Justification for the 
Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) and the AURORA 
study (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: 
An Assessment of Survival and Cardiovascular Events) examined the effect of statins in two 
specific patient populations who currently do not meet the guidelines for statin treatment, but 
nonetheless, are at high cardiovascular risk. This review outlines the JUPITER and AURORA 
trials, interprets the data and significance of the results, analyses the drawbacks and impact of 
both trials and delineates the potential for further clinical trials.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in the United States and 
other industrialized countries and in addition leads to substantial health-care expen-
ditures and morbidity.1 The American Heart Association projects that 80 million 
American adults experience one or more forms of cardiovascular disease (CVD), 
of whom 73 million have hypertension, 16.8 million have coronary heart disease 
(including 7.9 million with history of myocardial infarction), 6.5 million have expe-
rienced a stroke and 5.7 million have heart failure.1 The estimated cost to treat CVD 
in the United States in 2008 was US$475.3 billion.1 Over the last several decades, 
efforts to treat or prevent risk factors for CVD have substantially lowered rates of 
CVD-related mortality. HMG-CoA reductase inhibitors, or “statins”, have emerged 
as the predominant therapeutic strategy for preventing and treating CVD.
Several landmark trials from the 1990s established the beneficial effects of statins in 
reducing cardiovascular events in secondary prevention2–4 as well as for primary prevention 
among those with elevated levels of low-density lipoprotein-cholesterol (LDL-C)5 or 
with below average levels of high-density lipoprotein-cholesterol (HDL-C).6 However, 
lipid screening alone incompletely identifies individuals likely to benefit from statin 
therapy.7 Among statin-treated patients with established coronary heart disease, recent 
data suggest even lower LDL-C targets (such as 70 mg/dL) are associated with more 
favorable outcomes.8,9Vascular Health and Risk Management 2009:5 1034
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The beneficial effects of statins are usually attributed 
to their ability to reduce endogenous cholesterol synthesis; 
however, statins may have pleiotropic effects including reduc-
tion of inflammation, improvement of endothelial function, 
anti-oxidant properties and increased stability of atheroscle-
rotic plaques.10 These other mechanisms could also contribute 
to the significant reduction in cardiovascular morbidity and 
mortality achieved with statins.
Rosuvastatin pharmacology
Statins competitively inhibit hydroxy-methylglutaryl-
coenzyme A reductase (HMG-CoA reductase), the principal 
enzyme involved in cholesterol biosynthesis. Mevalonate, the 
product of HMG-CoA reductase reaction, is the precursor not 
only for cholesterol but also for many isoprenoid compounds 
vital for cellular growth and differentiation. Inhibition of 
HMG-CoA reductase and the resultant inhibition of these 
important pathways, appears to explain the pleiotropic 
effects of statins.
As reviewed by Kapur,11 there are several pharmaco-
logic properties that differentiate rosuvastatin from other 
statins. Rosuvastatin displays enhanced binding of HMG-
CoA reductase, leading to more potent inhibition of the 
enzyme. In addition, rosuvastatin is not entirely dependent 
on cytochrome P450 3A4 for metabolism, which may lead 
to improved clinical safety profile when used with other 
medications.
Rosuvastatin is currently approved for the treatment of 
high LDL-C, high total cholesterol and/or high triglyceride 
levels. The recommended starting dose ranges from 5 to 
20 mg individualized to patient factors and baseline LDL-C, 
with titration up to 40 mg for individuals who have not 
achieved LDL-C goal with 20 mg.
Early rosuvastatin efficacy trials
Rosuvastatin appears to be the most potent of the available 
statins, leading to both the greatest LDL-C lowering and 
HDL-C raising effects in the MERCURY I and II trials12,13 
and the STELLAR trial.14 In these studies, rosuvastatin 
also produced greater reductions in total cholesterol and 
nonHDL-C and produced similar or greater reductions in 
triglycerides compared to other statins in patients both with 
and without the metabolic syndrome. Like other statins, rosu-
vastatin has beneficial effects on advanced lipid biomarkers 
such as LDL particle size and number.
High-dose statins have been shown to demonstrate a slow-
ing or halting of progression of atherosclerosis as measured 
by carotid ultrasound, quantitative coronary angiography, 
or intravascular ultrasound.15–18 In the METEOR study, 
rosuvastatin led to a significant reduction in the rate of 
progression of maximum carotid intima-media thickness over 
2 years, even among “low-risk” middle-aged individuals with 
a low Framingham Risk Score.19 The ASTEROID study, which 
used rosuvastatin, was the first study to show that intensive 
statin therapy can induce regression of atherosclerotic plaque 
in the coronary arteries at prespecified intravascular ultra-
sound locations.20
The above studies established rosuvastatin as a potent 
and effective statin and piqued interest in larger randomized 
clinical trials with hard clinical endpoints.
HsCRP as a biomarker of CVD risk
Of the nearly 800,000 myocardial infarctions and 700,000 
strokes that occur in the United States each year, almost half 
of these events occur in apparently healthy men and women 
with levels of LDL-C that are below currently recommended 
thresholds for treatment with statins. Therefore, a need exists 
to improve risk assessment in asymptomatic individuals 
without overt evidence of hyperlipidemia, but who may 
nonetheless benefit from statin therapy.
Numerous biomarkers have been proposed to improve 
prediction of cardiovascular risk. One such biomarker, 
high-sensitivity C-reactive protein (hsCRP), is an inflam-
matory biomarker that has been shown to independently 
predict cardiovascular events21,22 across all Framingham 
Risk groups23,24 Therefore, hsCRP has been proposed as a 
novel screening strategy to detect high vascular risk even 
in the absence of hyperlipidemia and to improve global risk 
stratification.25
HsCRP is strongly associated with the metabolic syndrome 
and obesity,26 and because of the epidemic of obesity and meta-
bolic syndrome in the United States,27 it is likely that the preva-
lence of elevated hsCRP will increase as well. Weight loss28 and 
physical activity29 can both lower hsCRP levels and lifestyle 
changes are first line therapy in primary prevention to lower 
CVD risk. Statins also lower hsCRP levels providing support 
for the hypothesis that statins may have anti-inflammatory 
effects in addition to the lipid-lowering effects.30
The JUPITER clinical trial
JUPiTeR trial design
The JUPITER trial (Justification for the Use of statins in 
Prevention: an Intervention Trial Evaluating Rosuvastatin) 
sought to investigate whether statin therapy would reduce 
first cardiovascular events in individuals who have low 
levels of LDL-C (outside of current treatment guidelines Vascular Health and Risk Management 2009:5 1035
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for statin therapy), but are nonetheless at increased risk given 
hsCRP of  2.0 mg/L.31,32 The JUPITER trial was a multicenter, 
randomized, double-blinded, placebo-controlled trial conducted 
in 26 countries, the largest contributors of patients being the 
United States, United Kingdom, South Africa and Canada.
The study population consisted of men 50 years of age 
and women 60 years of age, who did not have any pre-existing 
history of CVD, with LDL-C of 130 mg/dL and an hsCRP 
level of  2.0 mg/L. Excluded from the study were those with 
previous or current use of lipid-lowering therapy, evidence 
of hepatic dysfunction (alanine aminotransferase level more 
than twice the upper limit of normal), creatinine 2.0 mg/dL, 
current use of postmenopausal hormone therapy, creatine 
kinase elevated to more than 3 times the upper limit of normal, 
diabetes, uncontrolled hypertension (either systolic blood 
pressure 190 mmHg or diastolic blood pressure 100 mmHg), 
cancer within 5 years of enrollment (except basal cell or 
squamous cell carcinoma of the skin), uncontrolled hypo-
thyroidism (thyroid-stimulating hormone level elevated to 
more than 1.5 times the upper limit of normal), triglyceride 
level 500 mg/dL, history of inflammatory conditions such 
as lupus, severe arthritis, inflammatory bowel disease, current 
use of immunosuppressive medications such as cyclosporine 
and tacrolimus and long-term use of glucocorticoids. Potentially 
eligible participants underwent a 4-week run-in phase during 
which they received the placebo and their compliance was 
assessed. Only those subjects who took more than 80% 
of all study tablets were defined as demonstrating good 
compliance and were subsequently enrolled in the study.
After screening approximately 90,000 adults (of which most 
were not eligible because of either an elevated LDL-C (52%) or 
a low hsCRP level [36%]), 17,802 apparently healthy men and 
women who met the inclusion criteria were ultimately random-
ized to receive either 20 mg of rosuvastatin daily or placebo. 
Follow-up visits were scheduled to occur at 13 weeks and 
subsequently, at 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months. 
The primary endpoint investigated in JUPITER was the occur-
rence of a first major cardiovascular event, defined as nonfatal 
myocardial infarction, nonfatal stroke, hospitalization for 
unstable angina, arterial revascularization procedure, or death 
from a cardiovascular cause. Secondary endpoints included 
the individual components of the primary endpoint as well as 
all-cause mortality.
JUPiTeR trial results
Although the study was designed to continue for a total of 
5 years, a prespecified interim efficacy analysis was per-
formed and the independent data and safety monitoring board 
voted to terminate the trial given the significantly favorable 
outcomes in the rosuvastatin treatment arm. At the time of 
study termination with a median follow-up time of 1.9 years, 
142 first major cardiovascular events had occurred in the 
rosuvastatin group as compared to 251 events in the placebo 
group. The rates of the primary endpoint were 0.77 and 
1.36 per 100 person-years of followup in the rosuvastatin and 
placebo groups, respectively (with a relative risk reduction of 
44%, hazard ratio [HR] of 0.56, 95% confidence interval [CI] 
0.46 to 0.69, P  0.00001). The rates of the other endpoints 
are summarized in Table 1. At 12 months, the rosuvastatin 
group had a 50% lower median LDL-C, a 37% lower hsCRP, 
a 17% lower triglyceride level and a 4% higher HDL-C level 
as compared to the placebo group.
The number of patients who would have needed to be treated 
(NNT) for 2 years to prevent one primary endpoint was 95 
and extrapolated to 5 years, the NNT is estimated at 25. These 
NNT values compare even more favorably with NNT values 
from other large-scale statin trials. For example, the 5-year 
NNT value for statin treatment of dyslipidemic individuals 
enrolled in the WOSCOPS and AFCAPS/TexCAPS primary 
prevention trials was 44 and 49 respectively.5,6 This suggests 
that the strategy of selecting individuals for statin therapy on 
the basis of an elevated hsCRP is effective. However, the NNT 
value at 5 years in the JUPITER trial is an extrapolated value 
as the trial was terminated after a median followup of only 
1.9 years, whereas the AFCAPS/TexCAPS and WOSCOPS 
trials had an average of ∼5 years of followup.
JUPITER is also the first large-scale randomized pro-
spective study to demonstrate that a statin reduces the risk 
of venous thromboembolism. Rosuvastatin lowered the risk 
of deep venous thrombosis or pulmonary embolism by 43% 
(95% CI, 0.37 to 0.86).33 Furthermore, there was no increased 
hemorrhagic stroke risk with rosuvastatin in the JUPITER 
trial. Therefore, statin therapy may provide a novel approach 
to preventing deep venous thrombosis and pulmonary embo-
lism without a bleeding risk.
All subgroups significantly benefited from rosuvastatin, 
including those who were previously considered “low-risk” such 
as women, those without metabolic syndrome, nonsmokers, 
those with Framingham risk scores of 10% or less, black and 
Hispanic populations, those with LDL-C level of 100 mg/dL 
or less and those with body mass indices less than 25 kg/m². 
JUPITER was the first statin prevention trial to show clear 
benefits in women (46% risk reduction, 95% CI 0.37 to 0.80), 
in Blacks and Hispanics (37% risk reduction, 95% CI 0.41 
to 0.98) and in the elderly (those above age 70 years, 39% 
risk reduction, 95% CI 0.46 to 0.82). For those with elevated Vascular Health and Risk Management 2009:5 1036
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hsCRP and no other major risk factor except for increased age, 
the benefit of rosuvastatin was similar to that for higher-risk 
individuals (39% risk reduction, P = 0.01).
There was no significant difference in the incidence of 
myopathy and newly-diagnosed cancer between the rosuvastatin 
and placebo groups. There was a small but significant increase 
in physician-reported diabetes in the rosuvastatin group (270 in 
rosuvastatin group and 216 in placebo group, P = 0.01), as 
well as a small but significant increase in the median value of 
glycated hemoglobin (5.9% and 5.8% respectively, P = 0.001). 
However, there was no significant difference between the two 
groups with respect to fasting blood glucose and glycosuria 
in the followup period. Therefore, further evaluation must be 
undertaken to better understand this possible effect. This small 
increase in diabetes has been observed in previous clinical trials 
of pravastatin, simvastatin and atorvastatin.
JUPiTeR unanswered questions
The JUPITER trial demonstrated that in apparently healthy 
men and women who do not have evidence of hyperlipidemia 
but who are nonetheless at increased risk given elevated 
hsCRP, rosuvastatin significantly reduced the risk of first 
major cardiovascular event and all-cause mortality.
Limitations of the study include the exclusion of indi-
viduals with low levels of hsCRP. We cannot know from the 
JUPITER trial whether individuals with both a low baseline 
hsCRP and low LDL-C would also have achieved a signifi-
cant event reduction with statin therapy. The JUPITER trial 
investigators made the decision not to include those with 
low baseline hsCRP based on a posthoc analysis from the 
AFCAPS/TexCAPS study which found that individuals with 
low LDL-C (149.1 mg/dL) and low hsCRP (1.6 mg/L) 
had low CVD event rates.7 Therefore it was felt by the study 
investigators that the NNT would be too great to enroll indi-
viduals with low hsCRP into JUPITER and that it would be 
unlikely to show a benefit among this subgroup, although the 
individuals in the AFCAPS/TexCAPS study may have been 
somewhat younger on average than the JUPITER participants 
(mean age 58 years in AFCAPS/TexCAPS vs median age of 
66 years in JUPITER). It still remains unclear whether all 
older adults regardless of hsCRP might benefit from statin 
therapy by virtue of increased baseline risk.
Similarly, men less than 50 years of age and women less 
than 60 years of age were excluded from the study. There-
fore, conclusions cannot be drawn from JUPITER whether 
younger individuals with elevated hsCRP and low LDL-C 
levels would also experience a significant event reduction 
with rosuvastatin therapy and thus the results of JUPITER 
should not necessarily be extrapolated to younger individuals. 
In a younger patient population with low LDL-C levels, the 
possible reduction in event rate that may be achieved with 
rosuvastatin therapy must be weighed against the risk of 
prolonged exposure to statin therapy.
Furthermore, the benefit of further reducing hsCRP level 
beyond LDL-C reduction is not entirely clear. Although 
hsCRP was substantially reduced in the rosuvastatin group, 
Table 1 Summary of JUPiTeR and AURORA trial results







JUPiTeR results N = 8901 N = 8901
Primary endpoint 0.77 1.36 44 0.00001
Nonfatal Mi 0.12 0.33 65 0.00001
Nonfatal stroke 0.16 0.31 48 0.003
Arterial revasc 0.38 0.71 46 0.0001
Mi, stroke, and CV death 0.45 0.85 47 0.00001
Death from any cause 1 1.25 20 0.02
AURORA results N = 1389 N = 1384
Primary endpoint 9.2 9.5 4 0.59
Nonfatal Mi 2.1 2.5 16 0.23
Nonfatal stroke 1.2 1.1 NA 0.42
Death from CV cause 7.2 7.3 0 0.97
Death from any cause 13.5 14 4 0.51
Death from non-CV causes 5.5 6 8 0.34
Abbreviations: Mi, myocardial infarction; revasc, revascularizations; CV, cardiovascular.Vascular Health and Risk Management 2009:5 1037
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LDL-C was also significantly reduced and the median LDL-C 
level achieved was 55 mg/dL. However, the reduction in event 
rate by rosuvastatin appeared to be greater than would have 
been anticipated by the magnitude of the LDL-C reduction. 
In posthoc analyses of the JUPITER trial, Ridker et al dem-
onstrated that the lowest event rates were among those who 
achieved both LDL-C level less than 70 mg/dL and hsCRP 
level less than 2.0 mg/L; however, those who did not achieve 
on-treatment hsCRP less than 2.0 mg/L were more likely to 
have higher baseline levels of hsCRP and were more likely 
to be smokers and have a higher body-mass index.34
In performing this posthoc statistical analyses comparing 
event rates based on categories of achieved on-treatment hsCRP 
and LDL-C levels, several such factors were adjusted for, 
including baseline LDL-C, baseline hsCRP, age, sex, smoking 
status, body-mass index, blood pressure, baseline HDL-C and 
parental history of premature coronary artery disease. However, 
given that this was a nonrandomized posthoc analysis, there 
may be residual confounding factors including the possibil-
ity that those with higher levels of baseline and on-treatment 
hsCRP may have more sedentary, with less healthier lifestyles. 
These types of subtle confounding factors differentiating “good 
health” vs “poorer health” are measured imprecisely and cannot 
be adequately adjusted for in an observational analysis.
Because rosuvastatin dramatically lowers both LDL-C 
and hsCRP, the JUPITER trial cannot be used to determine 
whether hsCRP reduction alone leads to reduced vascular 
risk. This hypothesis could be tested with agents that have 
targeted vascular anti-inflammatory effects but do not have 
proven LDL-C reducing effects. The JUPITER study did not 
prospectively titrate statin therapy to achieve the dual goals 
of hsCRP level 2.0 mg/L and LDL-C level 70 mg/dL. 
Therefore, further evaluation is required to determine whether 
titrating towards a specific goal hsCRP level is beneficial.
In summary, the JUPITER trial demonstrated that the 
hsCRP level may be a useful tool in selecting for individuals 
who could benefit from statin therapy and would otherwise 
not be candidates for statins under current treatment guide-
lines. Although lifestyle interventions such as weight loss and 
exercise can reduce hsCRP and remain critical for prevention, 
the JUPITER eligibility criteria (in terms of hsCRP screen-
ing and indications for statin treatment) are likely to impact 
future CVD prevention guidelines.
The AURORA clinical trial
AURORA trial design
The AURORA (A Study to Evaluate the Use of Rosuvas-
tatin in Subjects on Regular Hemodialysis: An Assessment 
of Survival and Cardiovascular Events) trial was a primary 
prevention study which examined the potential benefit of 
statins in another specific patient population at high CVD 
risk – end-stage renal disease (ESRD) patients on chronic 
hemodialysis.35 ESRD patients have previously been excluded 
from studies on statins because of their numerous comor-
bidities and issues of safety, leading to a paucity of data on 
these patients. However, CVD is very common in patients 
with renal insufficiency and, in particular, the rates of car-
diovascular morbidity and mortality are substantially higher 
among dialysis patients than in those without renal disease.36 
Therefore, there is a crucial need to find an effective method 
of preventing CVD in this particular patient population.
AURORA was a randomized, double-blinded, placebo-
controlled multicenter trial, with patients recruited from 
280 centers in 25 countries. The study population included 
men and women between 50 to 80 years of age with ESRD 
who had been treated with regular hemodialysis for at least 
3 months. Exclusion criteria included: statin therapy within 
the last 6 months, expected kidney transplantation within 
1 year, serious neoplastic, gastrointestinal, hematologic, 
metabolic (except diabetes), or infectious disease that was 
predicted to reduce survival to less than 1 year, a history of 
malignancy, active liver disease (defined as alanine amino-
transferase level more than three times the upper limit of 
normal), unexplained creatine kinase elevation to more than 
three times upper limit of normal and uncontrolled hypo-
thyroidism (defined by thyroid-stimulating hormone level 
greater than 1.5 times the upper limit of normal).
There were 2776 patients who met the inclusion criteria 
who were randomly assigned to rosuvastatin 10 mg or placebo. 
The two groups of patients were similar with respect to base-
line characteristics including age, mean duration of dialysis 
treatment, sex and race/ethnicity. Followup visits occurred 
3 months after randomization and then every 6 months there-
after. Mean length of followup was 3.2 years. No patients 
were lost to followup.
The primary endpoint investigated in AURORA was 
time to a major cardiovascular event, defined as nonfatal 
myocardial infarction, nonfatal stroke, or death from a car-
diovascular cause. Secondary endpoints included: all-cause 
mortality, death from noncardiovascular causes, death from 
noncardiovascular causes, cardiovascular event-free survival 
(ie,free from nonfatal myocardial infarction, nonfatal stroke, 
death from any cause), coronary or peripheral revasculariza-
tion and procedures performed for stenosis or thrombosis 
of arteriovenous grafts or fistulas that were being used for 
hemodialysis.Vascular Health and Risk Management 2009:5 1038
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AURORA trial results
A total of 804 patients had a major cardiovascular event 
during the followup period, of which 396 were in the rosu-
vastatin group and 408 were in the placebo group (9.2 and 
9.5 events per 100 person-years of followup respectively). 
There was no significant effect of treatment with rosuvastatin 
on the primary combined endpoint (HR 0.96; 95% CI 0.84 
to 1.11; p = 0.59). There was also no significant effect of 
treatment with rosuvastatin on the individual components 
of the primary endpoint. A summary of the AURORA trial 
results can be found in the Table. The lack of effect of rosu-
vastatin on the primary endpoint was consistent among all 
subgroups including those with diabetes, high LDL-C level, 
elevated hsCRP, hypertension and preexisting CVD. The lack 
of effect of rosuvastatin on the primary endpoint was also 
not influenced by overall time on hemodialysis.
At 3 months, LDL-C was reduced by 43% by rosuvas-
tatin as compared to only a 1.9% reduction in the placebo 
group (P  0.001 for comparison). At 3 months, rosuvastatin 
also reduced total cholesterol by 27% (as compared with a 
0.5% in the placebo group, P  0.001) and triglycerides by 
16% (as compared to a 0.9% increase in the placebo group, 
P  0.001). Median hsCRP level was elevated at baseline 
(4.8 mg/L in rosuvastatin group vs 5.2 mg/L in the placebo 
group). This was decreased by 12% by rosuvastatin at 
3 months (by 0.65 mg/L vs an increase of 0.21 mg/L in the 
placebo group, P  0.001).
There was no statistically significant increase in the inci-
dence of rhabdomyolysis or liver disease in the rosuvastatin 
group as compared to the placebo group. There was a small 
but statistically significant increase in the incidence of hemor-
rhagic stroke in diabetic patients who received rosuvastatin 
in the AURORA trial; this is consistent with findings in the 
4D study (Die Deutsche diabetes Dialyse Studie).37 In addi-
tion, there was no increased incidence of physician-reported 
diabetes as seen in the JUPITER study. Only 10 patients in 
the rosuvastatin group and fourteen patients in the placebo 
group were reported to have new-onset diabetes mellitus in 
the AURORA trial (P = 0.40).
AURORA trial unanswered questions
The AURORA trial demonstrated no cardiovascular benefit 
of rosuvastatin in ESRD patients on chronic hemodialysis 
despite improvement in surrogate biomarkers. These results 
from AURORA are comparable with the results from 
the previously published 4D study, which also examined the 
cardiovascular benefit of statins in hemodialysis patients. The 
4D study also showed no significant benefit of statin therapy 
on the composite primary endpoint of nonfatal myocardial 
infarction, fatal or nonfatal stroke and death from a cardio-
vascular cause in type 2 diabetes patients undergoing chronic 
hemodialysis. The lack of cardiovascular benefit from statins 
in both the AURORA trial and 4D trial suggests that CVD in 
hemodialysis patients may be different from that in the popu-
lation without renal disease or from those with milder forms 
of chronic kidney disease (CKD) (ie, CKD stages 1 to 3).
The pattern of cardiovascular events in hemodialysis 
patients also differs from that in the general population. 
In the general population, a majority of cardiovascular events 
are coronary events such as myocardial infarctions. In the 
hemodialysis population, however, only approximately 25% 
of cardiovascular events are myocardial infarctions.38 Rather, 
heart failure, sudden cardiac death and arrhythmias predomi-
nate in this population. Therefore, the anti-inflammatory and 
lipid-lowering effects of statins may not benefit a popula-
tion in which myocardial infarctions do not predominate. 
Rosuvastatin was shown to be ineffective in reducing the 
incidence of cardiovascular events in heart failure patients in 
the CORONA and the GISSI-HF trials.39,40 In these patients, 
myocardial infarctions were also not responsible for most of 
the deaths.
Many patients with ESRD on chronic dialysis have cal-
cification of the vascular tree, including medial calcification 
and valvular calcification, which may not be treatable with 
statins. While medial and intimal (atherosclerotic) calcifica-
tion may have some shared risk factors, the distinction of the 
two types of calcification is important because screening, 
treatment and prognosis may differ.41 Instead, issues related 
to hyperphosphatemia and hyperparathyroidism, both of 
which are not treatable by statins, may have a more signifi-
cant influence on medial vascular calcification. Indeed, the 
authors of the AURORA trial stated that a high phosphate 
level was one of the strongest risk factors for the occurrence 
of cardiovascular endpoints in their study. Similarly, left ven-
tricular hypertrophy (LVH) is common in ESRD patients and 
has been shown in previous studies to be a strong predictor 
of cardiovascular events in dialysis patients.42 It is unclear 
whether statins affect LVH and in fact, data on LVH were 
not demonstrated in AURORA.
An analogy can potentially be drawn between ESRD 
and calcific aortic stenosis, where statins seem to have little 
benefit once the disease process is advanced, but may be 
beneficial in earlier precursor stages. Degenerative aortic 
stenosis has many similarities to atherosclerotic plaque 
histologically and has many similar predisposing risk 
factors. Statin therapy has therefore been proposed as a way Vascular Health and Risk Management 2009:5 1039
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to slow the rate of progression of aortic stenosis given the 
similarity with atherosclerosis. However, in the SALTIRE 
study, treatment with atorvastatin 80 mg had no effect on the 
rate of progression of calcific aortic stenosis over 2 years of 
follow-up as assessed by Doppler echocardiography and by 
change in CT calcium score of the valve, despite reducing the 
LDL-C by more than 50%.43 This was further confirmed in 
the SEAS trial which found simvastatin 40 mg plus ezetimibe 
10 mg daily was ineffective at reducing overall events com-
pared with placebo among patients without hyperlipidemia 
that had calcific aortic stenosis,44 although ischemic events 
were reduced. These data suggests that statins reduce cardiac 
events related to atherosclerosis but not cardiac events related 
to other pathophysiologic mechanisms.
However, statins may be beneficial when given earlier in the 
disease process. Using observational data from medical records, 
Antonini-Canterin et al showed that statins reduce progression 
of aortic sclerosis and mild aortic stenosis, but not moderate 
aortic stenosis or greater.45 Analogous to statins reducing pro-
gression of aortic sclerosis but not significant aortic stenosis, 
statins may not benefit dialysis patients based on the fact that 
cardiovascular mortality increases progressively through the 
early stages of CKD and becomes exponentially higher in 
hemodialysis patients (almost 10 to 20 times higher than the 
general population). Therefore, it may be too late for statins 
to provide any benefit in dialysis patients, who have already 
attained such a high cardiovascular risk, in the same way that 
statins cannot reduce progression of a frankly stenotic valve.
In patients with CKD but perhaps not end-stage, statin 
therapy may slow the progression of kidney decline.46 In a 
posthoc analysis from the CARDS study,47 diabetics with 
moderately decreased estimated glomerular filtration rate 
of 30 to 60 mL/min/1.73 m2 experienced a 42% reduction 
in CVD events with atorvastatin treatment including a 61% 
reduction in stroke. A Cochrane review of CKD patients not 
receiving dialysis did confirm that statins overall significantly 
reduce the risk of all-cause and CVD mortality and appear 
to be safe in this population.48
Limitations of the AURORA trial include some of the 
exclusion criteria. Specifically, those who were already 
on a statin were excluded from the trial (this consisted of 
approximately 30% to 40% of patients on hemodialysis). 
This group, however, likely included those with a history of 
previous cardiovascular events and therefore could have been 
the most likely group to benefit from statin treatment.
Another limitation in this study was that only patients above 
50 years of age were included in this trial. It is possible that 
statins could have benefited younger CKD patients who start 
statin treatment early. This is in contrast to starting a statin in 
someone over the age of 50 years, who has been chronically ill 
for several years with multiple comorbidities, who has already 
been on dialysis for 3 years and has likely suffered the irrevers-
ible deleterious vascular effects of dialysis. Futhermore, the 
increase in cardiovascular risk among hemodialysis patients 
is disproportionately higher in young patients.
In addition, those who may undergo kidney transplanta-
tion within 1 year were excluded from the study. This likely 
represents a healthier population of ESRD patients on hemo-
dialysis who may have been more likely to benefit from statin 
therapy. Another limitation of this study is the possibility of 
insufficient statistical power. Lastly, approximately 50% of 
patients in AURORA discontinued treatment; this could have 
biased the effect of rosuvastatin towards a null result.
Clinical perspectives
Half of all cardiovascular events in the United States each 
year occur among individuals with normal or low LDL-C 
levels, suggesting that screening lipid levels alone incom-
pletely identifies individuals who are likely to benefit from 
statin therapy. In an attempt to reduce these potentially missed 
opportunities for instituting preventive therapy, the JUPITER 
and AURORA studies examined the effect of statins in two 
specific primary prevention patient populations who cur-
rently do not meet the guidelines for statin treatment, but 
nonetheless, are at higher cardiovascular risk than would be 
predicted by LDL-C alone.
The results from JUPITER have the potential to signifi-
cantly impact public health and prevention of cardiovascular 
disease, providing a rationale for broader use of statin therapy 
for primary prevention than currently recommended. A recent 
meta-analysis of over 10 clinical trials (including WOSCOPS, 
AFCAPS/TexCAPS, CARDS, JUPITER and others) together 
enrolling greater than 70,000 individuals without established 
CVD but with some CVD risk factors showed that treatment 
with statins over a mean 4.1 years was associated with a sig-
nificant 22% reduction in all-cause mortality, 30% reduction 
in the risk of major coronary events, a 19% reduction in the 
risk of major cerebrovascular events and no evidence of an 
increased risk of cancer.49
The absolute event rate, which in the JUPITER trial was 
moderate, must be taken into account when considering 
broader use of statins in the primary prevention population. 
A critical question is whether rosuvastatin therapy would be 
cost-effective and we await forthcoming cost-effectiveness 
analyses. Previous cost-effectiveness analyses for other pri-
mary prevention studies (ASCOT, WOSCOPS) have shown Vascular Health and Risk Management 2009:5 1040
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statin use to be cost-effective.50,51 The cost of expanding the 
use of statins may be at least partially offset by the poten-
tially significant reduction in the rates of hospitalization and 
arterial revascularization that would occur with rosuvastatin 
treatment as demonstrated in the JUPITER study.
Using data from the National Health and Nutrition Exami-
nation Survey (NHANES 1999–2004), we estimated that 
6.5 million additional adults could be potential candidates for 
initiating statin therapy according to the JUPITER criteria.52 
Using the JUPITER eligibility strategy, we estimate that 
260,000 CVD events could be prevented in the United States 
over 5 years. Rosuvastatin costs approximately US$1200/year 
for each individual and therefore, treating this entire subpopu-
lation would cost approximately US$7.8 billion/year.
It is generally thought that the significant reduction in 
CVD events conferred by statins is a “class-effect”, as event 
reduction has been shown with all 6 available statins on the 
US market, with the amount of benefit being related to the 
magnitude of LDL-C reduction and the patient’s absolute risk. 
As outlined above, clearly certain statins such as rosuvastatin 
are more potent in terms of LDL-C reduction and may be 
preferred in patients who have trouble reaching LDL-C goal; 
however there is no data yet to support that once an LDL-C 
goal such as 70 mg/dL is reached, that one statin would be 
preferred over another one. Thus for cost-effectiveness, one 
may consider treating with generic statin as first line choice 
if appropriate LDL-C target can be attained.
In addition to costs, the safety profile of statin therapy 
needs to be considered before a major expansion in statin 
use can take place. The JUPITER trial was terminated after 
a median follow-up of only 1.9 years; therefore, the possible 
(but unlikely) adverse effects of longer-term statin therapy 
need to be further evaluated. The marginal but significant 
increase in possible physician-reported diabetes that was 
demonstrated in the JUPITER trial and other previous statin 
trials also need to be further evaluated.
On the other hand, the AURORA trial did not show 
promising results for expanding the use of statins to dialysis 
patients. The pathogenesis of cardiovascular disease in hemo-
dialysis patients may differ from that in the general popula-
tion. Although in both subpopulations, the pathogenesis is 
multifactorial, consisting of calcification, inflammation and 
atherothrombosis, the degree to which each of these three 
components contributes to the process may differ substan-
tially. Therefore, the quest for new interventions to reduce 
cardiovascular risk in dialysis patients should be based on 
a more accurate understanding of the causal pathway of 
cardiovascular disease in dialysis patients.
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